NIKA PHARMACEUTICALS, INC (NIKA): auditor change — Nika Pharmaceuticals dismisses accountant OLAYINKA OYEBOLA & CO, appoints Boladale Lawal & Co

NIKA PHARMACEUTICALS, INC

Terminated OLAYINKA OYEBOLA & CO on Oct 2, 2024 after a discovery prompting reconsideration.
No services were performed by the prior accountant before termination.
Engaged Boladale Lawal & Co as independent auditor on Oct 5, 2024 to audit financial statements.
Exhibit 23.1 includes dismissal consent from the former accountant.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

NIKA PHARMACEUTICALS, INC dismissed OLAYINKA OYEBOLA & CO (Chartered Accountants) as its auditor.

Action: dismissal
Auditor: OLAYINKA OYEBOLA & CO (Chartered Accountants)
Successor: Boladale Lawal & Co (Chartered Accountants)

Exact text from the filing

nder the Exchange Act (17 CFR 240.13e -4(c)) Section 4 - Matters Related to Accountants and Financial Statements Item 4.01 Changes in Registrant’s Certifying Accountant. On October 2, 2024, Nika Pharmaceuticals, Inc. made a discovery, which led it to consider that it is in the best interest not to continue its engagement of independent accountant OLAYINKA OYEBOLA & CO (Chartered Accountants). No services had been performed by OLAYINKA OYEBOLA & CO (Chartered Accountants) prior to the termination of the engagement on October 2, 2024. On October 5, 2024, Nika Pharmaceuticals, Inc.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

NIKA PHARMACEUTICALS, INC engaged Boladale Lawal & Co (Chartered Accountants) as its auditor.

Action: engagement
Auditor: Boladale Lawal & Co (Chartered Accountants)

Exact text from the filing

On October 5, 2024, Nika Pharmaceuticals, Inc. engaged the firm of Boladale Lawal & Co (Chartered Accountants) to serve as the independent accountant to audit the company’s financial statements.

View on SEC.gov

Browse all auditor changes →

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-24-000131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.